Brookline Capital Acquisition II, a blank check company formed by Brookline Capital Markets targeting healthcare and defense, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The company plans to raise $100 million by offering 10 million units at $10. Each unit consists of one share of common stock and one right to receive one-tenth of one share upon the completion of an initial business combination.
Brookline Capital Acquisition II is led by Chairman Samuel Wertheimer, a Senior Scientific Advisor at Brookline Capital Markets. He is joined by CEO and Director Patrick Sturgeon, a Managing Partner at Brookline Capital Markets, and CFO and President Dimitre Genov, also a Managing Director at Brookline Capital. The SPAC plans to target a business in the healthcare and defense technology industries.
Management's previous SPAC, Brookline Capital Acquisition, merged with Apexigen (formerly Nasdaq: APGN) in 2022, which was delisted after being acquired by Pyxis Oncology in 2023.
The New York, NY-based company was founded in 2025 and plans to list on the Nasdaq under the symbol BCACU. Brookline Capital Markets is the sole bookrunner on the deal.
